0 0 0 0 0 0 0 0 0 1 3
OncoLUNG Dx - Final Report
Patient Information
Identification Data General Biochemistry Biochemistry
HRN: Hemolized Sample: No Realization
Blood Drawn Date:16-08-
LUN00004216 2025
ID Card: 136862994
Serum Tumor CT Scan Image
Markers
Personal Data CA 15.3 (U/mL): 209.0 Findings: None
0
Gender: Male CEA (ng/mL): 36.00
Age: 17 CYFRA 21-1 (ng/mL): 22.30
NSE (ng/mL): 28.00 Lifestyle
Comorbidities ProGRP (pg/mL): 3.00 Smoking Habits: 3 Years
Chronic Liver Disease: Yes SCC (ng/mL): 3.80 Alcohol: 8 months
Pemphigus/Psoriasis: No
Renal Failure: No
Outcome
Tumor Markers Results
Some Tumor Markers are outside the reference range and suggest malignancy.
High
Conclusions
WE SUGGEST NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH PROBABILITY
ADENOCARCINOMA OR LARGE-CELL LUNG CARCINOMA (LCLC). THE 2016 ICD-10-CM
DIAGNOSIS CODE IS C34.90 (MALIGNANT NEOPLASM OF UNSPECIFIED PART OF
UNSPECIFIED BRONCHUS OR LUNG).
This report has been generated from the data entered on 14-02-2018 16:18:46 UTC/GMT.
Disclaimer
This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Lung Cancer has been
developed for the exclusive use by healthcare professionals, and solely as a Clinical
Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm
bears a Sensitivity = 93.5%, Specificity = 96.2%, PPV = 97.6%, NPV = 89.9%. Please
note, negativity of the Tumor Markers does not exclude at 100% the possibility of a
malignant epithelial tumor.
0 0 0 0 0 0 0 0 0 1 3
8
Bioprognos SL
Technical
Benet Mateu, 40 - 08034 Barcelona Responsible
(Spain) Email: info@bioprognos.com Lorena Lendinez
Website: www.bioprognos.com Chief Scientific
Officer Bioprognos
SL
